Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

GlaxoSmithKline

Generic Valtrex, Avandia's collapse and huge legal reserves impact revenues, earnings

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GSK 4Q10

4Q Revenues: $11.4 billion (-13%)

4Q Loss: $955 million(earnings of $2.6 billion in 4Q09)

FY Revenues: $44.0 billion (-1%)

FY Earnings: $2.9 billion (-67%)

Comments: U.S. pharma sales for the year dropped 11% to $11.9 billion, while European sales dropped 7% to $10.1 billion. Emerging markets rose 22% to $5.5 billion in that span. The vaccine segment overall grew 15% to $6.7 billion. Generic exposure for Valtrex and Avandia’s continuing death-spiral impacted revenues for 4Q and FY. Valtrex sales were $152 million (-60%) for 4Q and $823 (-60% from $2.0 billion) for FY. The 4Q loss was driven by $3.2 billion in legal costs and $450 million in restructuring costs. GSK announced plans to sell off non-core OTC consumer health brands that add up to around $750 million in annual sales. The company also sold its share in Quest diagnostics for $1.1 billion (after tax) this week and sold its interest in Zovirax to Valeant for $300 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters